Arcadia Biosciences Logo
US0390142042
A2JSFW
RKDA

Arcadia Biosciences

Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 5,47 € (+3117,65%). La mediana è 5,47 € (+3117,65%).

Acquista
  4
Mantieni
  1
Vendi
  0

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Arcadia Biosciences secures $4 million through private placement

    Arcadia Biosciences raised approximately $4 million in gross proceeds through a private placement, selling 3,883,496 common shares or prepaid warrants at $1.03 per share. The offering also included Series A-1 and A-2 investment options with an exercise price of $0.91; A-1 will be exercisable after shareholder approval, A-2 is immediately exercisable. H.C. Wainwright & Co. acted as sole placement agent; net proceeds are intended for working capital and general corporate purposes. The transaction is notable given a current market capitalization of $2.08 million; the company reports a current ratio of 3.79 and plans to file registration statements for resale. » Altro su de.investing.com


  • Arcadia Biosciences secures $4 million through private placement

    Arcadia Biosciences sold 3,883,496 common shares or prepaid warrants at a price of $1.03 each, generating gross proceeds of approximately $4 million. The transaction includes A‑1 and A‑2 warrants with an exercise price of $0.91; A‑1 warrants are valid for five years following shareholder approval, A‑2 warrants are immediately exercisable and expire 24 months after the registration statement becomes effective. H.C. Wainwright & Co. is acting as exclusive placement agent; the proceeds are intended for working capital and general corporate purposes, and the closing is expected subject to customary conditions. » Altro su de.investing.com


  • Arcadia Biosciences dismisses Deloitte and appoints Ramirez Jimenez International as new auditor

    Arcadia Biosciences dismissed Deloitte & Touche as its independent auditor effective March 30 and appointed Ramirez Jimenez International CPAs (RJI) to audit the quarter ended March 31, 2026 and the fiscal year ended December 31, 2026. Deloitte’s reports for 2024 and 2025 contained no adverse opinions but included an explanatory paragraph regarding going concern; the company disclosed material weaknesses in internal control over financial reporting for 2025, notably a lack of segregation of duties and deficient IT controls due to reduced staffing. Deloitte was authorized to provide RJI with information on the matters; Arcadia reports no disagreements with Deloitte. » Altro su de.investing.com


  • Arcadia Biosciences stock rises after termination of Roosevelt deal

    Arcadia Biosciences stock rose about 9% in pre-market trading after Roosevelt Resources terminated the securities exchange agreement dated December 4, 2024, as of December 24, 2025, in accordance with the contract. CEO T.J. Schaefer said the company will resume the review process for strategic alternatives and pointed to operational streamlining, cost reductions and growth of the coconut water brand Zola. The company still holds roughly 2.7 million common shares of Above Food Ingredients and expects additional consideration related to the sale of GoodWheat, which, together with the NASDAQ listing, should favor strategic transactions. » Altro su de.investing.com


  • Arcadia Biosciences schedules annual general meeting for December 19, 2025

    Arcadia Biosciences sets its 2025 annual general meeting for December 19 and says it will publish the time, location and agenda in the definitive proxy statement filed with the SEC. Shareholders must submit proposals or director nominations in writing by close of business on November 3, 2025. The company is keeping the annual meeting separate from a possible special meeting related to a Securities Exchange Agreement with Roosevelt Resources. In addition, CFO Mark Kawakami resigned effective September 12; Thomas J. Schaefer was appointed interim CFO and will take on the role in addition to his duties as CEO with no change to his compensation. Analysts see significant upside, with a $12 price target versus the current price of $4.14. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Arcadia Biosciences ha registrato ricavi pari a 1,43 Mln € e un utile netto di 1,55 Mln €
(EUR) settembre 2026
YoY
Ricavi 1,43 Mln 28,83%
Utile lordo 758,37K 112,91%
Utile netto 1,55 Mln 112,41%
EBITDA 1,55 Mln 111,92%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
281,57K €
Numero di azioni
1,55 Mln
Massimo/minimo a 52 settimane
3,53 € - 0,10 €
Dividendi No
Beta
0,59
Rapporto P/E
-0,02
Rapporto PEG
0,00
Rapporto P/B
0,50
Rapporto P/S
0,06

Profilo aziendale

Arcadia Biosciences, Inc. produce e commercializza prodotti per la salute e il benessere a base vegetale negli Stati Uniti. L'azienda sviluppa miglioramenti genetici delle colture, principalmente del grano, per migliorare l'economia agricola attraverso il miglioramento delle prestazioni delle colture in campo, nonché il loro valore come ingredienti alimentari, prodotti per la salute e il benessere e la loro idoneità per applicazioni industriali. La società è stata costituita nel 2002 e ha sede a Davis, in California.

Nome
Arcadia Biosciences
CEO
Thomas J. Schaefer
Sede centrale Davis, tx
Stati Uniti
Sito web
Settore
Beni di prima necessità
Industria
Prodotti alimentari
Quotazione in borsa
15/05/2015
Dipendenti 8

Simboli di borsa

Borsa Simbolo
NASDAQ
RKDA
Frankfurt
17DN.F
München
17DN.MU
🍪

Parqet  usa i cookie. Scopri di più